Glycosaminoglycan synthesis and structure as targets for the prevention of calcific aortic valve disease

Cardiovasc Res. 2007 Oct 1;76(1):19-28. doi: 10.1016/j.cardiores.2007.05.014. Epub 2007 May 17.

Abstract

Calcific aortic valve disease is frequently driven by ageing and the obesity-associated metabolic syndrome, and the increasing impact of these factors indicates that valve disease will become a cardiovascular disease of considerable significance. This disease is now thought to be an active cell-based disease process, which may therefore be amenable to therapeutic intervention. Some similarities are apparent with atherosclerosis. The accumulation of lipid, possibly by retention by proteoglycans and the attraction of inflammatory cells by hyaluronan, may be common to the early stages of both pathologies. The synthesis and structure of glycosaminoglycans, proteoglycans, and hyaluronan are exquisitely regulated, and the signalling pathways controlling these processes may provide tissue-specific opportunities for concomitant prevention of atherosclerosis and calcific aortic valve disease.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Aortic Valve / metabolism*
  • Aortic Valve Stenosis / metabolism*
  • Arteriosclerosis / metabolism
  • Calcinosis / metabolism*
  • Glycosaminoglycans / antagonists & inhibitors
  • Glycosaminoglycans / biosynthesis*
  • Glycosaminoglycans / chemistry
  • Humans
  • Hyaluronic Acid / metabolism
  • Lipid Metabolism
  • Signal Transduction / physiology*

Substances

  • Glycosaminoglycans
  • Hyaluronic Acid